Updated:
Jubilant Biosys
Jubilant Biosys is a Contract Research, Development and Manufacturing Organization founded in 2004 in Bengaluru, India. The company operates as a subsidiary of...
Jubilant Biosys
Jubilant Biosys is a Contract Research, Development and Manufacturing Organization founded in 2004 in Bengaluru, India. The company operates as a subsidiary of Jubilant Pharmova. It provides drug discovery and development services across various therapeutic areas, including integrated drug discovery, medicinal and synthetic chemistry, biology services, and development and manufacturing options.
General information
Firm type
Integrated CRDMO
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Additional offices
Mumbai, India · Seattle, WA, United States · Beijing, China
Sector focus
Frequently asked questions
What services does Jubilant Biosys offer?
Jubilant Biosys provides integrated drug discovery and development services, from target identification and hit-to-lead chemistry through preclinical development and clinical trial support. The firm works across therapeutic areas including oncology, CNS disorders, and infectious diseases.
How is Jubilant Biosys related to the Jubilant Bhartia Group?
Jubilant Biosys is a wholly owned subsidiary of the Jubilant Bhartia Group, an Indian conglomerate with businesses in pharmaceuticals, food, and oil and gas. The group's pharmaceutical manufacturing and chemical production capabilities provide downstream integration for Jubilant Biosys' drug development projects.
Where does Jubilant Biosys operate?
Jubilant Biosys has offices in San Francisco, Mumbai, Seattle, and Beijing. Its largest research facility is in Bangalore, India, employing over 1,500 scientists and researchers.
What types of clients does Jubilant Biosys serve?
The firm serves global pharmaceutical companies, including top 20 pharma firms, as well as biotechnology companies ranging from startups to established players.
Does Jubilant Biosys have capabilities in AI and machine learning?
Yes, Jubilant Biosys has invested in AI and machine learning for drug discovery, including collaborations with academic partners, announced in 2023.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: